Clarify Pharma PLC Acquisition of Shares (4107H)

TIDMPSYC

RNS Number : 4107H

Clarify Pharma PLC

24 November 2022

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Press Release

24 November 2022

Clarify Pharma PLC

("Clarify Pharma" or "The Company")

Acquisition of Shares in Atai Life Sciences and Compass Pathways

Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, is pleased to announce it has acquired shares to the value of GBP250,000 in each of Atai Life Sciences Inc (NASDAQ: ATAI) and Compass Pathways PLC (NASDAQ: CMPS) as part of its investment strategy.

Atai Life Sciences Inc is a leading biotech company specialised in psychedelic-based drugs and has prominent backing from venture capitalists, including entrepreneur and venture capitalist Peter Thiel. Atai's pipeline features nine programs, four of which are in the clinical testing stage. The company's lead drug candidate, RL-007, is being evaluated in a Phase 2 clinical study as a potential treatment for schizophrenia. Furthermore, Atai's Perception Neuroscience unit partnered with Otsuka, the Japanese drugmaker, to develop R-ketamine in treating depression. This represented the first major collaboration between a psychedelic-focused biotech and a big pharmaceutical company. Atai has also acquired and made several strategic investments in companies in the sector.

Compass Pathways PLC was founded in 2015 to support the research and development of psilocybin therapy which combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support for the treatment of mental health challenges. Compass Pathways conducted the largest clinical trial in the history of psilocybin-assisted therapy with a Phase 2 study evaluating a synthesised formulation of psilocybin, COMP360, in treatment-resistant depression. This research is now into late-stage testing. Compass Pathways has also initiated a Phase 2 study of the therapy in treating post-traumatic stress disorder at The Institute of Psychiatry, Psychology & Neuroscience at King's College London.

Jonathan Bixby, Executive Chairman of Clarify Pharma, said: "I am delighted to announce Clarify Pharma's purchase of shares in two trailblazing companies which are conducting pioneering research into psychedelic-assisted therapeutic treatment. Clarify Pharma continues to pursue new and exciting opportunities in the sector and is focused on delivering value for shareholders as investors continue to gain confidence in the regulatory environment for alternative treatments."

For further information please contact:

 
 Clarify Pharma 
 Jon Bixby                             via Tancredi [phone] 
 
  Executive Chairman 
                                      ------------------------------ 
 First Sentinel 
                                      ------------------------------ 
 Corporate Adviser 
 
  Brian Stockbridge                    [phone] 
                                      ------------------------------ 
 Tennyson Securities 
                                      ------------------------------ 
 Corporate Broker 
 
  Peter Krens                          [phone] 
                                      ------------------------------ 
 Tancredi Intelligent Communication 
                                      ------------------------------ 
 Media Relations 
 
  Catrina Daly 
 
  Salamander Davoudi                     [phone] 
 
  [e-mail]        [phone] 
                                      ------------------------------ 
 

About Clarify Pharma PLC:

Listed on the Aquis Stock Exchange in London , Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing.

The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation.

https://www.clarifypharma.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEAXFDAAFAFFA

(END) Dow Jones Newswires

November 24, 2022 02:00 ET (07:00 GMT)